Tubular proteinuria as an indicator for elevated cardiovascular risk

Details for Australian Patent Application No. 2004292775 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Schrader, Joachim

Agent Watermark

Pub. Number AU-A-2004292775

PCT Pub. Number WO2005/051379

Priority 03027312.2 26.11.03 EP

Filing date 26 November 2004

Wipo publication date 9 June 2005

International Classifications

A61K 31/415 (2006.01) - 1,2-Diazoles

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 31/403 (2006.01) - condensed with carbocyclic rings, e.g. carbazole

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 31/4178 (2006.01)

A61K 31/4184 (2006.01)

Event Publications

15 June 2006 PCT application entered the National Phase

  PCT publication WO2005/051379 Priority application(s): WO2005/051379

24 June 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004292778-Extended use combination comprising estrogens and progestins

2004292773-Diaryl urea derivatives in the treatment of protein kinase dependent diseases